AVGO vs PGEN Stock Comparison
PGEN currently leads AVGO in this stock comparison, with AIQ scores of 55 vs 52. The clearest difference is momentum, while AVGO has the stronger risk resilience profile.
What is the main difference between AVGO and PGEN?
PGEN leads the current stock comparison as Precigen, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Broadcom Inc. vs Precigen, Inc.
PGEN leads
PGEN leads by 3 AIQ points, primarily on Momentum and Value, but the lead has narrowed from 6 points over 30 sessions.
Fragile: 3 of 6 evidence groups support PGEN, its lead is narrowing, and its current signal state is conflicted.
Broadcom Inc.
Precigen, Inc.
The Algovestiq AIQ Score currently favors PGEN over AVGO, 55 versus 52 as of Nov 15, 2026. PGEN's advantage is driven primarily by stronger momentum and value, while AVGO holds the stronger risk resilience profile. PGEN also shows the weaker technical structure relative to its 50-day moving average. 3 of 6 covered evidence groups favor PGEN today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 3 points. PGEN lead: Weakening — the AIQ differential moved from 6 to 3 points over 30 sessions.
Compare Broadcom Inc. and Precigen, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare AVGO and PGEN against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Risk Resilience47 vs 31AVGO +16
- Momentum40 vs 55PGEN +15
- Value50 vs 63PGEN +13
- Quality69 vs 60AVGO +9
3 of 6 evidence groups favor PGEN. PGEN’s edge is concentrated in momentum and value; AVGO keeps a meaningful risk resilience edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Momentum -2, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 6 active signals are unchanged.
No factor moved materially.
New signals
- ADX Trend Strengthening — neutral, trend, medium horizon
- Keltner Channel Breakdown — bearish, volatility, short horizon
PGEN's lead widened by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — AVGO and PGEN both carry a full feed there.
The central trade-off
PGEN (Precigen, Inc.): the stronger current systematic profile, led by momentum and value.
AVGO (Broadcom Inc.): the counter-case, on risk resilience, quality, technicals.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
PGENPGEN on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
PGENPGEN on combined revenue and EPS growth.
Value
PGENPGEN on the peer-relative Value factor, by 13 points.
Momentum
PGENPGEN on the Momentum factor, by 15 points.
Lower downside
AVGOAVGO on Risk Resilience, by 16 points.
Analyst upside
PGENPGEN on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | AVGO | PGEN | Note |
|---|---|---|---|
| Implied upside to target | +48.5% | +164.3% | PGEN has more room |
| Target dispersion | +48.5% | 0% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 51 | 4 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor PGEN. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 52 vs 55 |
| Fundamentals | PGENon balance | revenue growth 33.4% vs 34.9%; EPS growth 40.3% vs 66.7%; TTM ROE 13.1% vs 42.7%; gross margin 68.8% vs 91%; operating margin 48.4% vs 21.4% — PGEN takes 4 of 5 decided legs, not all of them |
| Valuation | PGEN | Value 50 vs 63 |
| Technicals | AVGO | Price vs 50-day 0.5% vs -32.6%; vs 200-day -5.6% vs -14% |
| Risk Resilience | AVGO | Risk Resilience 47 vs 31 |
| Analyst expectations | PGEN | Target upside 48.5% vs 164.3% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of AVGO and PGEN and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 3 points. (argues the conclusion is provisional)
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on PGEN.
How the comparison changed
120 daily snapshots · May 27 – Nov 13PGEN lead: Weakening — the AIQ differential moved from 6 to 3 points over 30 sessions.
- Today
- PGEN +3
- 52 vs 55
- 7 sessions ago
- PGEN +12
- 50 vs 62
- 30 sessions ago
- PGEN +6
- 55 vs 61
- 90 sessions ago
- AVGO +1
- 59 vs 58
The lead changed hands once in this window, most recently on Aug 19 when PGEN moved ahead of AVGO.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 2 bearish / 2 neutral, conflicted
Only AVGO
- Death Cross Active — bearish, trend, long horizon (6.38%)
- ADX Trend Weakening — neutral, trend, medium horizon
- Accumulation Pattern — bullish, volume, medium horizon (1.18x)
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
1 bullish / 2 bearish / 2 neutral, conflicted
Only PGEN
- Golden Cross Active — bullish, trend, long horizon (27.69%)
- ADX Trend Strengthening — neutral, trend, medium horizon
- Keltner Channel Breakdown — bearish, volatility, short horizon
Both carry 2 more signals that do not separate them: ATR Expansion - Breakout Mode, Beta Spike Warning.
PGEN leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -4.76%, AIQ 0 points).
Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -2.58%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1AVGO closes the Momentum gap — currently 15 points behind, the largest single contributor to PGEN's edge.
- 2AVGO's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3PGEN's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once.
- 4The narrowing continues — the lead has already given back 3 points over 30 sessions, and a further 3-point move would eliminate PGEN's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
PGEN leads on balance| Metric | AVGO | PGEN |
|---|---|---|
| Revenue growth (YoY) | 33.4% | 34.9% |
| EPS growth (YoY) | 40.3% | 66.7% |
| Gross margin | 68.8% | 91% |
| Operating margin | 48.4% | 21.4% |
| Return on equity (TTM) | 13.1% | 42.7% |
| Debt to equity | 0.6 | 1.18 |
Performance
Split across windows| Metric | AVGO | PGEN |
|---|---|---|
| 1 week (5 sessions) | 18.2% | 1.6% |
| 1 month (20 sessions) | 5.6% | -28.9% |
| 3 months (63 sessions) | -11.6% | -30.7% |
| 6 months (126 sessions) | -18.4% | 2.7% |
| Year to date | 0.3% | 8.6% |
| 1 year (252 sessions) | -2.3% | 12.9% |
Technicals
AVGO has the stronger structure| Metric | AVGO | PGEN |
|---|---|---|
| RSI (14) | 53.2 | 34.2 |
| ADX (14) | 23 | 28.8 |
| Price vs 50-day | 0.5% | -32.6% |
| Price vs 200-day | -5.6% | -14% |
| Volatility (1M, annualized) | 70% | 127% |
Risk
AVGO is the more resilient| Metric | AVGO | PGEN |
|---|---|---|
| Beta | 2.21 | 1.62 |
| Sharpe ratio | 0.21 | 0.57 |
| Sortino ratio | 0.29 | 0.87 |
| Max drawdown | -39.5% | -50.7% |
| Current drawdown | -27.9% | -47% |
| Annualized volatility | 48.6% | 85.4% |
| Value at risk (95%) | -4.6% | -7.2% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, AVGO or PGEN?
On the Algovestiq AIQ Score, PGEN is the stronger of the two as of Nov 15, 2026, scoring 55 against AVGO's 52. The edge comes from momentum and value. AVGO is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is AVGO or PGEN the better buy right now?
PGEN carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 3 points. Treat the lead as provisional.
Why does the AIQ Score favor PGEN over AVGO?
The composite weights Quality, Value, Momentum and Risk Resilience. AVGO leads Risk Resilience by 16 points; PGEN leads Momentum by 15 points; PGEN leads Value by 13 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, AVGO or PGEN?
Analyst price targets imply +48.5% upside for AVGO and +164.3% for PGEN, so the Street currently favors PGEN. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, AVGO or PGEN?
PGEN is the better-valued of the two on the peer-relative Value factor. PGEN on the peer-relative Value factor, by 13 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, AVGO or PGEN?
PGEN on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, AVGO or PGEN?
PGEN on the Momentum factor, by 15 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, AVGO or PGEN?
AVGO is the more resilient of the two, so the other name carries the higher downside risk. AVGO on Risk Resilience, by 16 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is AVGO more profitable than PGEN?
The profitability evidence is mixed: gross margin 68.8% vs 91%; operating margin 48.4% vs 21.4%; ttm roe 13.1% vs 42.7%. AVGO leads on one measure and PGEN on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is PGEN's lead over AVGO getting stronger or weaker?
PGEN lead: Weakening — the AIQ differential moved from 6 to 3 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-08-19, when PGEN moved ahead of AVGO.
What would change the AVGO vs PGEN verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: AVGO closes the Momentum gap — currently 15 points behind, the largest single contributor to PGEN's edge; AVGO's Death Cross Active resolves — a bearish trend rule currently active against it; PGEN's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once; the narrowing continues — the lead has already given back 3 points over 30 sessions, and a further 3-point move would eliminate PGEN's advantage entirely.
What do the current signals say about AVGO and PGEN?
AVGO: 2 bullish / 2 bearish / 2 neutral, conflicted. PGEN: 1 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on AVGO is Death Cross Active (bearish, long horizon). On PGEN it is Golden Cross Active (bullish, long horizon).
Compare AVGO and PGEN with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.